| Company Name: |
BOC Sciences |
| Tel: |
16314854226 |
| Email: |
info@bocsci.com |
2-Chloro-3-(trifluoromethyl)-N-((S)-phenyl((S)-piperidin-2-yl)methyl)benzamide hydrochloride manufacturers
- SSR504734 HCl
-
- $41.00
-
2026-07-15
- CAS:615571-23-8
- Purity: 99.93%
- Supply Ability: 10g
|
| | 2-Chloro-3-(trifluoromethyl)-N-((S)-phenyl((S)-piperidin-2-yl)methyl)benzamide hydrochloride Basic information |
| | 2-Chloro-3-(trifluoromethyl)-N-((S)-phenyl((S)-piperidin-2-yl)methyl)benzamide hydrochloride Chemical Properties |
| storage temp. | 4°C, away from moisture and light | | form | Solid | | color | White to off-white |
| | 2-Chloro-3-(trifluoromethyl)-N-((S)-phenyl((S)-piperidin-2-yl)methyl)benzamide hydrochloride Usage And Synthesis |
| Uses | SSR504734 is an orally active, selective and reversible inhibitor of human, rat, and mouse GlyT1 (IC50=18, 15, and 38nM, respectively). SSR504734 shows anti-schizophrenia, anti-anxiety and anti-depression activities[1]. | | in vivo | SSR504734 (i.p. and p.o.; 1-100 mg/kg; once) treatment shows good oral bioavailability[1].
SSR504734 (i.p.; 30 mg/kg; once) induces a rapid and significant decrease of specific glycine uptake[1].
SSR504734 (i.p.; 10 mg/kg; once) increases extracellular levels of Glycine in the prefrontal cortex (PFC) of freely moving rats[1]. | Animal Model: | Male Sprague-Dawley rats[1] | | Dosage: | 1-100 mg/kg | | Administration: | Intraperitoneal injection and oral gavage.; 1-100 mg/kg; once | | Result: | Showed ID50 values of 5.0 and 4.6mg/kg for i.p. and p.o. treatments, respectively. |
| Animal Model: | Male Sprague-Dawley rats[1] | | Dosage: | 30 mg/kg | | Administration: | Intraperitoneal injection; 30 mg/kg; once | | Result: | Maintained at about 80% inhibition from 1 to 7h after administration. |
| Animal Model: | Male Sprague-Dawley rats[1] | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection; 10 mg/kg; once | | Result: | Produced a rapid and sustained increase in PFC extracellular levels of glycine. |
| | IC 50 | hGlyT1: 18 nM (IC50); rGlyT1: 15 nM (IC50) | | References | [1] Ronan Depoortère, et al. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology. 2005 Nov;30(11):1963-85. DOI:10.1038/sj.npp.1300772 |
| | 2-Chloro-3-(trifluoromethyl)-N-((S)-phenyl((S)-piperidin-2-yl)methyl)benzamide hydrochloride Preparation Products And Raw materials |
|